WallStreetZenWallStreetZen

NYSE: ZTS
Zoetis Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Zoetis earnings were $2.6B for the trailing 12 months ending Jun 30, 2025, with 13.9% growth year over year. The latest ZTS earnings report on Jun 30, 2025 announced Q2 2025 earnings of $718.0M, up 13.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ZTS reported annual earnings of $2.5B, with 6.1% growth. The next ZTS earnings date is Nov 3, 2025.

ZTS past earnings growth

How has ZTS's earnings growth performed historically?

Company
13.89%
Industry
28.88%
Market
34.44%
ZTS's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ZTS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ZTS's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ZTS earnings history

Current Revenue
$9.4B
Current Earnings
$2.6B
Current Profit Margin
27.8%
ZTS's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

ZTS Return on Equity

Current Company
53.2%
Current Industry
18%
Current Market
30.7%
ZTS's Return on Equity (53.2%)... subscribe to Premium to read more.
High Return on Equity Performance

ZTS undefined

Current Company
18.3%
Current Industry
7%
ZTS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ZTS announces earnings.

ZTS undefined

Current Company
31.7%
Current Industry
13.9%
ZTS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ZTS vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ZTS$4.01B$2.61B+11.35%$5.82
TAK$8.01B$916.39M-3.46%$0.29
HLN$3.12B$1.87B+3.82%$0.41
TEVA$1.93B-$158.00MN/A-$0.14
NBIX$569.90M$348.30M+9.41%$3.48
View Top Pharmaceutical Stocks

ZTS earnings dates

Next earnings date
Nov 3, 2025

Zoetis Earnings Reports & History FAQ

What were Zoetis's earnings last quarter?

On ZTS's earnings call on Invalid Date, Zoetis (NYSE: ZTS) reported Q2 2025 earnings per share (EPS) of $1.61, up 17.52% year over year. Total ZTS earnings for the quarter were $718.00 million. In the same quarter last year, Zoetis's earnings per share (EPS) was $1.37.

If you're new to stock investing, here's how to buy Zoetis stock.

When does Zoetis report earnings?

The next ZTS earnings call is Invalid Date. Add ZTS to your watchlist to be reminded of Zoetis's next earnings date.

Is Zoetis profitable or losing money?

As of the last Zoetis earnings report, Zoetis is currently profitable. Zoetis's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $2.61 billion, a 11.43% increase year over year.

What was ZTS's earnings growth in the past year?

As of Zoetis's earnings date in Invalid Date, Zoetis's earnings has grown 13.89% year over year. This is 14.98 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 28.88%. ZTS earnings in the past year totalled $2.61 billion.

What are Zoetis's earnings expectations?

The current EPS estimate for Zoetis's earnings report in Invalid Date is $1.64.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.